Form 8-K - Current report:
SEC Accession No. 0001104659-25-061311
Filing Date
2025-06-23
Accepted
2025-06-23 06:06:52
Documents
17
Period of Report
2025-06-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2518511d1_8k.htm   iXBRL 8-K 59281
2 EXHIBIT 2.1 tm2518511d1_ex2-1.htm EX-2.1 649074
3 EXHIBIT 10.1 tm2518511d1_ex10-1.htm EX-10.1 139195
4 EXHIBIT 99.1 tm2518511d1_ex99-1.htm EX-99.1 19630
8 GRAPHIC tm2518511d1_ex99-1img01.jpg GRAPHIC 14405
9 GRAPHIC tm2518511d1_ex99-1img02.jpg GRAPHIC 14619
  Complete submission text file 0001104659-25-061311.txt   1242136

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA enzn-20250620.xsd EX-101.SCH 3005
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE enzn-20250620_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE enzn-20250620_pre.xml EX-101.PRE 22352
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2518511d1_8k_htm.xml XML 3246
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-12957 | Film No.: 251062863
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)